We are live on
!
Find out more
Lord, Abbett & Co Portfolio holdings
AUM
$30.6B
1-Year Est. Return
57.44%
This Fund
S&P 500
This Quarter
Est. Return
-1.79%
1 Year Est. Return
+57.44%
3 Year Est. Return
+215.76%
5 Year Est. Return
+368.6%
10 Year Est. Return
+2,376.62%
AUM
$37.5B
AUM Growth
-$6.38B
(-15%)
Cap. Flow
-$5.67B
Cap. Flow
% of AUM
-15.11%
Top 10 Holdings %
Top 10 Hldgs %
16.75%
Holding
717
New
113
Increased
155
Reduced
240
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Shell
SHEL
|
+$259M |
| 2 |
Allstate
ALL
|
+$258M |
| 3 |
Mastercard
MA
|
+$187M |
| 4 |
Costco
COST
|
+$170M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$153M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$263M |
| 2 |
DHR.PRA
Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A
DHR.PRA
|
+$257M |
| 3 |
SIVB
SVB Financial Group
SIVB
|
+$210M |
| 4 |
CIT
CIT Group Inc.
CIT
|
+$207M |
| 5 |
RDS.A
Royal Dutch Shell PLC ADS Class A
RDS.A
|
+$205M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.09% |
| 2 | Healthcare | 14.39% |
| 3 | Financials | 13.54% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 8.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Intellia Therapeutics
NTLA
$1.49B
| $26.4M | 0.07% |
362,750
-584,084
| -62% | -$49.5M |
|
302
Harley-Davidson
HOG
$2.58B
| $26.1M | 0.07% |
663,022
-133,631
| -17% | -$5.15M |
|
303
Criteo S.A. Ordinary Shares
CRTO
$1.1B
| $26.1M | 0.07% |
957,709
-835,379
| -47% | -$26.6M |
|
304
Entergy
ETR
$50.2B
| $25.8M | 0.07% |
441,640
+2,340
| +0.5% | +$128K |
|
|
AZEK
305
DELISTED
The AZEK Co
AZEK
| $25.7M | 0.07% |
1,036,286
-98,658
| -9% | -$3.1M |
|
|
CERE
306
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $25.6M | 0.07% |
729,850
+685
| +0.1% | +$20K |
|
307
JB Hunt Transport Services
JBHT
$25.5B
| $25.4M | 0.07% |
+126,464
| New | +$25.2M |
|
|
MRTX
308
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $25.3M | 0.07% |
308,285
-189,155
| -38% | -$19.3M |
|
309
Fiverr
FVRR
$321M
| $25.2M | 0.07% |
+331,375
| New | +$26.3M |
|
310
GitLab
GTLB
$5.83B
| $25M | 0.07% |
+458,967
| New | +$27.4M |
|
311
TaskUs
TASK
$556M
| $24.6M | 0.07% |
640,565
-954
| -0.1% | -$33.6K |
|
312
Dutch Bros
BROS
$9.03B
| $24.6M | 0.07% |
445,000
+290,182
| +187% | +$14.8M |
|
313
Sarepta Therapeutics
SRPT
$1.57B
| $24.4M | 0.07% |
312,782
-492,198
| -61% | -$37.7M |
|
314
Otis Worldwide
OTIS
$27.4B
| $23.7M | 0.06% |
308,422
-1,550
| -0.5% | -$124K |
|
315
Axalta
AXTA
$7.66B
| $23.6M | 0.06% |
959,141
-1,165,182
| -55% | -$32.6M |
|
316
Sensata Technologies
ST
$6.74B
| $23.1M | 0.06% |
+454,644
| New | +$25.9M |
|
317
Ultragenyx Pharmaceutical
RARE
$2.45B
| $22.8M | 0.06% |
313,744
+63
| +0% | +$4.38K |
|
318
The Bancorp
TBBK
$2.79B
| $22.6M | 0.06% |
796,280
-429,510
| -35% | -$12.4M |
|
319
Simpson Manufacturing
SSD
$7.72B
| $22.5M | 0.06% |
206,468
-164,404
| -44% | -$19.5M |
|
320
Aecom
ACM
$9.3B
| $22.5M | 0.06% |
+292,670
| New | +$21.5M |
|
321
DexCom
DXCM
$31.5B
| $22.4M | 0.06% |
175,444
-1,291,068
| -88% | -$141M |
|
322
Corteva
CTVA
$52.6B
| $21.7M | 0.06% |
377,257
-101,393
| -21% | -$5.18M |
|
323
Teradyne
TER
$57.6B
| $21.4M | 0.06% |
180,750
+13,500
| +8% | +$1.71M |
|
324
FIGS
FIGS
$1.79B
| $21.3M | 0.06% |
990,124
+490,227
| +98% | +$9.77M |
|
325
Old Dominion Freight Line
ODFL
$44.1B
| $21.2M | 0.06% |
141,814
-651,750
| -82% | -$101M |
|
Similar funds
Lord, Abbett & Co's Q1 2022 Portfolio in Review
As of Q1 2022, Lord, Abbett & Co held 717 positions worth $37.5B, down 15% from $43.9B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Lord, Abbett & Co withdrew a net $5.67B in Q1 2022, closing 120 positions and reducing 240 holdings. Its most notable exit was Netflix, an estimated $263M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lord, Abbett & Co opened a new position in Shell worth $268M.
- Lord, Abbett & Co's largest Q1 2022 buy was Shell: 4,875,112 shares worth $268M.
- Lord, Abbett & Co added most to Mastercard in Q1 2022, an estimated $187M increase.
- Lord, Abbett & Co's biggest Q1 2022 reduction was SVB Financial Group, cutting an estimated $210M.
- Lord, Abbett & Co fully exited Netflix in Q1 2022, selling an estimated $263M.
- Lord, Abbett & Co's ten largest holdings make up 17% of its $37.5B portfolio in Q1 2022.
- Lord, Abbett & Co opened 113 new positions and closed 120 in Q1 2022.
- Lord, Abbett & Co's portfolio value fell 15% quarter-over-quarter to $37.5B.
Based on Lord, Abbett & Co's 13F filing for Q1 2022, filed 13 May 2022.